High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. 1996

D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.

Despite its rarity by routine karyotypic analysis, cryptic t(12;21)(p12-13;q22) translocation leading to TEL/AML1 fusion has been recognized as the most frequent genetic rearrangement in childhood acute lymphoblastic leukemia (ALL) in two recent studies, one from France and the other from the United States. To estimate the frequency of this abnormality in the Chinese population, we studied 41 children with ALL and 17 with acute myeloid leukemia (AML) in two medical centers in Taiwan, using the reverse transcriptase polymerase chain reaction (RT-PCR) assay. Results of this analysis demonstrated a 17% frequency of this translocation in the ALL population overall and 19% in patients with B-lineage ALL, similar to previous findings in Caucasian children. None of the patients with AML had TEL/AML1 fusion transcripts. In addition to its association with the B-lineage immunophenotype, TEL/AML1 was also correlated with a low presenting leukocyte count and favorable age (1-10 years). These findings, combined with earlier reports, indicate that TEL/AML1 fusion is the most frequent genetic abnormality in childhood ALL, regardless of race. Molecular diagnosis of t(12;21)-positive ALL may identify a subgroup of patients who do not require intensive treatment for cure.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002881 Chromosomes, Human, Pair 12 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 12

Related Publications

D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
August 1997, International journal of hematology,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
February 1999, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
June 1995, Blood,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
March 1997, Leukemia,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
June 2008, The Kaohsiung journal of medical sciences,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
December 1995, Blood,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
July 1999, Blood,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
December 1997, Leukemia & lymphoma,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
June 1997, British journal of haematology,
D C Liang, and T B Chou, and J S Chen, and S A Shurtleff, and J E Rubnitz, and J R Downing, and C H Pui, and L Y Shih
July 2013, Blood,
Copied contents to your clipboard!